Neuren Bags RDA Designation from FDA For Trofinetide

Neuren Pharmaceuticals Limited (ASX: NEU) secures Rare Pediatric Disease designation for trofinetide from the United States Food and Drug Administration (or FDA) for the treatment of Rett syndrome.

  • The RPD designation from FDA may make the sponsor eligible to receive a Priority Review Voucher, which can be used to obtain FDA review of a New Drug Application for another product in an expedited period of six months.

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK